.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Obtain formulation and manufacturing information
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Covington
Cerilliant
Queensland Health
McKesson
UBS
McKinsey
Cantor Fitzgerald
Boehringer Ingelheim
Teva

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,645,459

« Back to Dashboard

Which drugs does patent 7,645,459 protect, and when does it expire?


Patent 7,645,459 protects ATELVIA and is included in one NDA. There has been one Paragraph IV challenge on Atelvia.

This patent has seventy-three patent family members in thirty-one countries.

Summary for Patent: 7,645,459

Title:Dosage forms of bisphosphonates
Abstract:Oral dosage forms of a bisphosphonate comprised of a safe and effective amount of a pharmaceutical composition comprising a bisphosphonate, a chelating agent, and, means for effecting delayed release of the bisphosphonate and the chelating agent in the lower gastrointestinal tract provide delivery of the pharmaceutical composition to the lower gastrointestinal tract of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between bisphosphonates and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of the bisphosphonate and the chelating agent to the lower GI tract, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies.
Inventor(s): Dansereau; Richard John (Cilncinnati, OH), Burgio, Jr.; David Ernest (Liberty Township, OH)
Assignee: The Procter & Gamble Company (Cincinnati, OH)
Application Number:11/106,816
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Delivery; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Apil
ATELVIA
risedronate sodium
TABLET, DELAYED RELEASE;ORAL022560-001Oct 8, 2010ABRXYesYes7,645,459► SubscribeY TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,645,459

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,409,615Low dosage forms of risedronate or its salts► Subscribe
7,645,460Dosage forms of risedronate► Subscribe
8,535,718Dosage forms of bisphosphonates► Subscribe
8,409,614Low dosage forms of risedronate or its salts► Subscribe
8,246,989Dosage forms of bisphosphonates► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,645,459

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway20065969► Subscribe
Norway20075834► Subscribe
South Korea101280138► Subscribe
South Korea20110018465► Subscribe
South Korea101388777► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Daiichi Sankyo
Argus Health
Cantor Fitzgerald
US Army
Express Scripts
Dow
Chinese Patent Office
Mallinckrodt
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot